LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Global Sepsis Diagnostics Market Driven by Increasing Prevalence of Bacterial Infections

By LabMedica International staff writers
Posted on 17 Oct 2022
Image: The global sepsis diagnostics market is expected to surpass USD 1.10 billion by 2027 (Photo courtesy of Pexels)
Image: The global sepsis diagnostics market is expected to surpass USD 1.10 billion by 2027 (Photo courtesy of Pexels)

Sepsis is a potentially fatal condition that occurs when the body's response to an infection causes tissue damage. When the body's infection-fighting processes activate, organs function poorly and abnormally. Sepsis can lead to septic shock, resulting in a significant drop in blood pressure that can cause severe organ damage and death. Sepsis diagnostics include instruments, lab tests, various technologies, and others that are used to diagnose sepsis by examining the patient for signs of infection or organ damage. The global sepsis diagnostics market is expanding due to factors such as the prevalence of the COVID-19 pandemic, an increase in geriatric population, a rise in the prevalence of bacterial infections such as tuberculosis, and increased regulatory approvals for technologically advanced sepsis diagnostics products. As a result, the global sepsis diagnostics market, which was valued at USD 0.65 billion in 2021, is projected to grow at a significant CAGR of 9.60% from 2022 to 2027, to reach USD 1.11 billion.

These are the latest findings of DelveInsight (Las Vegas, NV, USA), a market research firm.

One of the key drivers of the sepsis diagnostics market has been the COVID-19 pandemic. According to the World Health Organization (WHO) data published on 1 July 2022, there were 545,226,550 confirmed cases of COVID-19 across the world. COVID-19 has well-known effects on the respiratory system, with the majority of victims requiring hospitalization for pneumonia of various severity, although almost all other organ systems can be impacted. This is consistent with a mix of sepsis and direct viral invasion. Therefore, sepsis diagnosis is required to verify or check for signs of any infection or organ damage with the disease. Thus, the surge in COVID-19 pandemic cases has boosted the demand for sepsis diagnostics, and further increase in COVID-19 cases is expected to increase the demand for tools, reagents, and test kits for sepsis detection, resulting in growth of the sepsis diagnostics market.

Based on product type, the instruments & kits segment of the sepsis diagnostics market is expected to record a significant growth during the forecast period. Furthermore, the increased regulatory approvals for technologically advanced sepsis diagnostics products may boost the region's overall sepsis diagnostics market. North America is expected to dominate the global sepsis diagnostics market in 2021 and will continue to dominate the market throughout the forecast period due to rising prevalence of bacterial infections such as tuberculosis and increase in regulatory approvals for technologically-advanced sepsis diagnostics products.

Related Links:
DelveInsight 

Gold Member
Fibrinolysis Assay
HemosIL Fibrinolysis Assay Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Autoimmune Liver Diseases Assay
Microblot-Array Liver Profile Kit
New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more